Takeda, Sarepta double down on a biotech partner's platform to engineer better AAV capsids by mapping out their structure
When Aravind Asokan and Mavis Agbandje-McKenna first pulled together their respective research at the University of North Carolina-Chapel Hill and the University of Florida on engineering adeno-associated virus vectors and started StrideBio in 2015, the FDA was still two years away from an eventual groundbreaking first approval for an AAV gene therapy.
But even then — and moreso since — preclinical and clinical studies had exposed the glaring room for improvement in the way genes are delivered.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 158,500+ biopharma pros reading Endpoints daily — and it's free.